September 11, 2017 / 12:55 PM / a month ago

BRIEF-Checkpoint Therapeutics receives orphan drug designation for CK-101

Sept 11 (Reuters) - Checkpoint Therapeutics Inc:

* Checkpoint Therapeutics receives orphan drug designation for ck-101 for the treatment of egfr mutation-positive non-small cell lung cancer

* Checkpoint Therapeutics Inc - ‍ck-101 is currently being studied in phase 1 dose-escalation portion of a phase 1/2 clinical study​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below